Eligibility for Anti-Amyloid Treatment in a Population-Based Cohort Study of Aging (P5-6.006)
Rioghna R. Pittock(Mayo Clinic), Maria Vassilaki(Mayo Clinic), Vijay K. Ramanan(Mayo Clinic in Arizona), Prashanthi Vemuri(Mayo Clinic in Arizona), Ronald C. Petersen(Mayo Clinic in Arizona), David S. Knopman(Mayo Clinic), Jonathan Graff-Radford(Mayo Clinic), Clifford R. Jack(Mayo Clinic), Jeremiah A. Aakre(Mayo Clinic), Anna Castillo(Mayo Clinic)
Cited by 0
Related Papers
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|18.9k
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Mild cognitive impairment as a diagnostic entity
|Journal of Internal Medicine|2004|7.8k
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
|Journal of Internal Medicine|2004|5k